Focused therapeutic area Solvonis Therapeutics is a clinical-stage biopharmaceutical company concentrating on high-burden neuropsychiatric conditions, notably Alcohol Use Disorder and PTSD. This presents opportunities to engage with CROs, contract manufacturers, and specialty investors aligned with CNS and addiction research.

Small team, high leverage With 2-10 employees and a London-listed profile, the company may rely on strategic partnerships, outsourced expertise, and selective collaboration deals to accelerate development. This suggests value in outreach around collaboration frameworks, licensing discussions, and co-development opportunities.

Funding and growth potential Current funding of $13M against modest revenue (<$1M) indicates a growth-focused financing trajectory. Sales opportunities could include investor relations support, strategic partnerships, and consulting on grant opportunities, DAR funding, or research collaborations to extend runway.

US investor engagement Water Tower Research has been appointed to boost US investor reach, signaling active efforts to broaden liquidity and visibility in major markets. This opens doors for US-focused sales conversations around partnerships, equity story refinement, and potential strategic collaborations with US-based partners.

Technology and outreach readiness The company uses modern collaboration and web technologies (Microsoft 365, Framer, HTTP/3) and emphasizes acute, durable interventions over chronic maintenance therapies. This suggests receptiveness to digital outreach, data-driven storytelling, and early-stage partnership pitches that align with innovative CNS programs and repurposed/notable compounds.